zanubrutinib,obinutuzumab
roche,beigene,biogen
['lymsm', 'rosewood']
congress #asco22 | q&amp;a , was asked about the significant drop in response rate in the crossover portion of the rosewood trial. a: in part, we need to better understand the mechanisms of resistance in #fl, particularly in relation to single agent therapy. #lymsm
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm